Your browser doesn't support javascript.
loading
The continuous evolution of SARS-CoV-2 in South Africa: a new lineage with rapid accumulation of mutations of concern and global detection
Cathrine Scheepers; Josie Everatt; Daniel G. Amoako; Houriiyah Tegally; Constantinos Kurt Wibmer; Anele Mnguni; Arshad Ismail; Boitshoko Mahlangu; Bronwen E. Lambson; Simone I Richardson; Darren P Martin; Eduan Wilkinson; James Emmanuel San; Jennifer Giandhari; Nelia Manamela; Noxolo Ntuli; Prudence Kgagudi; Sandile Cele; Sureshnee Pillay; Thabo Mohale; Upasana Ramphal; Yeshnee Naidoo; Zamantungwa Khumalo; Gaurav Kwatra; Glenda Gray; Linda-Gail Bekker; Shabir Madhi; Vicky Baillie; Wesley C Van Voorhis; - Network for Genomic Surveillance South Africa (NGS-SA); Florette Treurnicht; Marietje Venter; Koleka Mlisana; Nicole Wolter; Alex Sigal; Carolyn Williamson; Nei-yuan Hsiao; Nokukhanya Msomi; Tongai Maponga; Wolfgang Preiser; Zinhle Makatini; Richard Lessells; Penny L. Moore; Tulio De Oliveira; Anne von Gottberg; Jinal N. Bhiman.
Afiliação
  • Cathrine Scheepers; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service, Johannesburg, South Africa
  • Josie Everatt; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Daniel G. Amoako; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Houriiyah Tegally; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Constantinos Kurt Wibmer; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Anele Mnguni; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Arshad Ismail; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Boitshoko Mahlangu; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Bronwen E. Lambson; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Simone I Richardson; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Darren P Martin; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
  • Eduan Wilkinson; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • James Emmanuel San; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Jennifer Giandhari; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Nelia Manamela; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Noxolo Ntuli; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Prudence Kgagudi; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Sandile Cele; Africa Health Research Institute, Durban, South Africa
  • Sureshnee Pillay; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Thabo Mohale; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Upasana Ramphal; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Yeshnee Naidoo; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Zamantungwa Khumalo; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Gaurav Kwatra; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Johannesburg, South Africa
  • Glenda Gray; South African Medical Research Council, Cape Town, South Africa
  • Linda-Gail Bekker; Desmond Tutu HIV Centre, Cape Town, South Africa
  • Shabir Madhi; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Johannesburg, South Africa
  • Vicky Baillie; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Johannesburg, South Africa
  • Wesley C Van Voorhis; Center for Emerging and Re-emerging Infectious Diseases (CERID), University of Washington, Washington State, United States
  • - Network for Genomic Surveillance South Africa (NGS-SA);
  • Florette Treurnicht; Division of Virology, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
  • Marietje Venter; Zoonotic arbo and Respiratory virus research programme, Department Medical Virology, University of Pretoria
  • Koleka Mlisana; National Health Laboratory Service (NHLS), South Africa
  • Nicole Wolter; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Alex Sigal; Africa Health Research Institute, Durban, South Africa
  • Carolyn Williamson; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa;
  • Nei-yuan Hsiao; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
  • Nokukhanya Msomi; National Health Laboratory Service (NHLS), South Africa
  • Tongai Maponga; Division of Medical Virology, Stellenbosch University, Faculty of Medicine and Health Sciences, Tygerberg, Cape Town, South Africa
  • Wolfgang Preiser; Division of Medical Virology, Stellenbosch University, Faculty of Medicine and Health Sciences, Tygerberg, Cape Town, South Africa
  • Zinhle Makatini; Division of Virology, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.
  • Richard Lessells; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Penny L. Moore; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Tulio De Oliveira; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Anne von Gottberg; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Jinal N. Bhiman; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21262342
ABSTRACT
Global genomic surveillance of SARS-CoV-2 has identified variants associated with increased transmissibility, neutralization resistance and disease severity. Here we report the emergence of the PANGO lineage C.1.2, detected at low prevalence in South Africa and eleven other countries. The emergence of C.1.2, associated with a high substitution rate, includes changes within the spike protein that have been associated with increased transmissibility or reduced neutralization sensitivity in SARS-CoV-2 VOC/VOIs. Like Beta and Delta, C.1.2 shows significantly reduced neutralization sensitivity to plasma from vaccinees and individuals infected with the ancestral D614G virus. In contrast, convalescent donors infected with either Beta or Delta showed high plasma neutralization against C.1.2. These functional data suggest that vaccine efficacy against C.1.2 will be equivalent to Beta and Delta, and that prior infection with either Beta or Delta will likely offer protection against C.1.2.
Licença
cc_no
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo diagnóstico / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo diagnóstico / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...